0000899243-20-014475.txt : 20200528
0000899243-20-014475.hdr.sgml : 20200528
20200528195351
ACCESSION NUMBER: 0000899243-20-014475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200526
FILED AS OF DATE: 20200528
DATE AS OF CHANGE: 20200528
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Latterich Martin
CENTRAL INDEX KEY: 0001808986
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36003
FILM NUMBER: 20923513
MAIL ADDRESS:
STREET 1: C/O HISTOGEN INC.
STREET 2: 10655 SORRENTO VALLEY ROAD, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Histogen Inc.
CENTRAL INDEX KEY: 0001383701
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203183915
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 16745 WEST BERNARDO DRIVE
STREET 2: SUITE 250
CITY: San Diego
STATE: CA
ZIP: 92127
BUSINESS PHONE: (858) 376-2600
MAIL ADDRESS:
STREET 1: 16745 WEST BERNARDO DRIVE
STREET 2: SUITE 250
CITY: San Diego
STATE: CA
ZIP: 92127
FORMER COMPANY:
FORMER CONFORMED NAME: Conatus Pharmaceuticals Inc.
DATE OF NAME CHANGE: 20140729
FORMER COMPANY:
FORMER CONFORMED NAME: Conatus Pharmaceuticals Inc
DATE OF NAME CHANGE: 20061214
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-26
0
0001383701
Histogen Inc.
HSTO
0001808986
Latterich Martin
C/O HISTOGEN INC.
10655 SORRENTO VALLEY RD., STE 200
SAN DIEGO
CA
92121
0
1
0
0
See Remarks
Common Stock
2020-05-26
4
J
0
11951
0.00
A
11951
D
Stock Option (right to buy)
3.70
2016-10-07
4
J
0
28684
0.00
A
2026-10-07
Common Stock
28684
28684
D
Stock Option (right to buy)
3.84
2018-03-12
4
J
0
14342
0.00
A
2028-03-12
Common Stock
14342
14342
D
Shares of common stock of the corporation formerly known as Histogen Inc. ("Histogen") were converted into shares of common stock of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of January 28, 2020, by and among the Issuer, Chinook Merger Sub, Inc. and Histogen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Histogen common stock was exchanged for 1.4342 shares of the Issuer's common stock (the "Conversion"). Immediately following the merger, the Issuer changed its name to Histogen Inc. All share numbers reflect the one-for-ten reverse stock split (the "Reverse Split") effected by the Issuer immediately prior to the completion of the merger.
Shares subject to the option vest in 48 equal monthly installments. Shares subject to the option and the exercise price have been adjusted based upon the Conversion and Reverse Split.
Shares subject to the option vest in 48 equal monthly installments. Shares subject to the option and the exercise price have been adjusted based upon the Conversion and Reverse Split.
Vice President, Technical Operations
/s/ Richard W. Pascoe as attorney-in-fact for Martin Latterich
2020-05-28